Ménière's disease is a condition of the inner ear. About 1 in a 1,000 people develop Ménière's disease. Generally, this condition starts in one ear only. The other ear is also affected at some stage in about 4 in 10 cases. The disease is named after a French doctor called Prosper Ménière who first described the disease in the 1860s.
Three endogenous antigenic targets, all integral membrane glycoproteins of podocytes, have been identified including the polyspecific receptor megalin in Heymann nephritis, neutral endopeptidase in alloimmune neonatal membranous nephropathy, and the phospholipase A2 receptor in idiopathic membranous nephropathy.
Meniere’s disease has a prevalence of about 200 cases/100,000 persons in the United States, or in other words, about 0.2 % of the population. The prevalence increases with age, rather linearly. It can affect anyone at any age but it most commonly begins between the ages of 40 and 60.
Gentamicin injection into the middle ear offers a safe and reasonably effective method for chemical labyrinthectomy for people with intractable vertigo willing to risk hearing loss.Vestibular nerve section controls vertigo with minimal risk of hearing loss. Labyrinthectomy is effective in controlling vertigo and is useful for older people with nonserviceable hearing.
Major research on disease:
Classic Ménière’s disease (MD) is manifested clinically by the symptoms of episodic vertigo associated with fluctuating hearing loss, tinnitus, and fullness all in the same ear.Meniere’s disease is a chronic (long-term) disease, but treatments and lifestyle changes can help to ease the symptoms.